SCHEMBL4715522

SCHEMBL4715522

Cc1ccc(-n2c(=O)ccc3c2cc(C(N)=O)n3Cc2cccc(Cl)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RGS4 P49798 1/20 0.48
RGS8 P57771 1/20 0.48
KDM4E B2RXH2 2/20 0.46
BRD4 O60885 5/20 0.44
CCR2 P41597 2/20 0.43
TP53 P04637 2/20 0.43
RXFP1 Q9HBX9 1/20 0.43
PLA2G2A P14555 3/20 0.42
MAPT P10636 3/20 0.42
PLA2G1B P04054 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ATG4B Q9Y4P1 1/20 0.42
F10 P00742 1/20 0.41
LMNA P02545 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4715116 0.91 CCR2 (0.55) RGS4RGS8BRD4CCR2TP53
SCHEMBL4715213 0.91 CCR2 (0.51) RGS4RGS8KDM4EBRD4CCR2
SCHEMBL4718447 0.90 BRD4 (0.49) RGS4RGS8BRD4CCR2TP53
SCHEMBL4716291 0.87 NOD2 (0.52) RGS4RGS8KDM4EBRD4TP53
SCHEMBL4714667 0.84 PLA2G10 (0.47) RGS4RGS8KDM4EBRD4CCR2
SCHEMBL4711667 0.82 KDM4E (0.41) KDM4EBRD4CCR2PLA2G2AMAPT
SCHEMBL5119050 0.82 CCR2 (0.62) CCR2MAPT
SCHEMBL4717022 0.80 CCR2 (0.49) RGS4RGS8KDM4EBRD4CCR2
SCHEMBL4711188 0.80 BRD4 (0.53) RGS4RGS8KDM4EBRD4CCR2
SCHEMBL4712174 0.80 MAPT (0.51) KDM4EBRD4CCR2MAPTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US claimed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US claimed
US-7456286-B2 Bicyclic heteroaromatic compounds as kinase inhibitors UCB PHARMA, S.A. (BE) 2008-11-25 US disclosed
EP-1549648-B1 BICYCLIC HETEROAROMATIC COMPOUNDS AS KINASE INHIBITORS UCB PHARMA SA (BE) 2008-11-12 EP disclosed
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors CELLTECH R&D LIMITED (GB) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122212-A1 Bicyclic heteroaromatic compounds as kinase inhibitors MAP2K2, MAP2K7, MAP2K3 RGS4 2669/4885RGS8 2068/4885KDM4E 2030/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.